Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Cash (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Change in Cash for 11 consecutive years, with -$18.2 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 176.94% to -$18.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$87.4 million through Dec 2025, down 164.27% year-over-year, with the annual reading at -$87.4 million for FY2025, 164.27% down from the prior year.
  • Change in Cash for Q4 2025 was -$18.2 million at Cartesian Therapeutics, down from -$16.9 million in the prior quarter.
  • The five-year high for Change in Cash was $132.0 million in Q3 2024, with the low at -$34.0 million in Q3 2023.
  • Average Change in Cash over 5 years is -$659500.0, with a median of -$8.8 million recorded in 2021.
  • Peak annual rise in Change in Cash hit 7098.83% in 2022, while the deepest fall reached 989.29% in 2022.
  • Over 5 years, Change in Cash stood at -$588000.0 in 2021, then crashed by 989.29% to -$6.4 million in 2022, then surged by 57.97% to -$2.7 million in 2023, then crashed by 144.73% to -$6.6 million in 2024, then crashed by 176.94% to -$18.2 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$18.2 million, -$16.9 million, and -$20.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.